Convalescent plasma: a valid option in the treatment of COVID-19?
Insights in Clinical and Cellular Immunology · 2020
DOI: 10.29328/journal.icci.1001012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Insights in Clinical and Cellular Immunology, 2020. Verfasst von Liu Genjiao und 1 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In the late of 2019, there is an outbreak of novel coronavirus disease (COVID-19) in Wuhan, China. The patients appear respiratory symptoms, fever, and cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death.
Zitieren
APA
Genjiao, L., & Shuang, L. (2020). Convalescent plasma: a valid option in the treatment of COVID-19?. Insights in Clinical and Cellular Immunology. https://doi.org/10.29328/journal.icci.1001012
Vancouver
Genjiao L, Shuang L. Convalescent plasma: a valid option in the treatment of COVID-19?. Insights in Clinical and Cellular Immunology. 2020. doi:10.29328/journal.icci.1001012
BibTeX
@article{Genjiao2020,
author = {Genjiao, Liu and Shuang, Li},
title = {Convalescent plasma: a valid option in the treatment of COVID-19?},
journal = {Insights in Clinical and Cellular Immunology},
year = {2020},
doi = {10.29328/journal.icci.1001012}
}
EUVIMED